Patents by Inventor Paul Zarek

Paul Zarek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS TO MODULATE T CELL RESPONSES
    Publication number: 20170143726
    Abstract: Described are uses of A2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing T-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents. The application provides methods of treatment and prevention based on the long term effects of the compounds on T cell responses.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 25, 2017
    Inventors: Jonathan D. Powell, Charles George Drake, Paul Zarek
  • Adenosine receptor agonists and antagonists to modulate T cell responses
    Patent number: 9585957
    Abstract: Described are uses of A2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing T-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents. The application provides methods of treatment and prevention based on the long term effects of the compounds on T cell responses.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: March 7, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan D Powell, Charles George Drake, Paul Zarek
  • Adenosine Receptor Agonists and Antagonists to Modulate T Cell Responses
    Publication number: 20110027295
    Abstract: Described are uses of A2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing T-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents. The application provides methods of treatment and prevention based on the long term effects of the compounds on T cell responses.
    Type: Application
    Filed: September 8, 2008
    Publication date: February 3, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan D Powell, Charles George Drake, Paul Zarek